Tonix Pharmaceuticals Hol... (TNXP)
7.78
-0.08 (-1.02%)
At close: Mar 03, 2025, 12:30 PM
Tonix Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
| Revenue | 7.77M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 4.74M | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M | 21.29M | 38.97M | 48.16M | 27.66M | 10.89M | 6.66M | 3.38M | n/a | 17K | 7.11K |
| Gross Profit | 3.03M | -112.09M | -92.31M | -50.51M | -28.83M | -26.32M | -21.29M | -38.97M | -48.16M | -27.66M | -10.89M | -6.66M | -3.38M | n/a | -17K | -7.11K |
| Operating Income | -118.38M | -112.09M | -92.31M | -50.51M | -28.83M | -26.32M | -21.29M | -38.97M | -48.16M | -27.66M | -10.89M | -6.66M | -3.38M | -17.72K | -30.87K | -21.13K |
| Interest Income | n/a | 1.87M | 25K | 48K | 210K | 233K | 168K | 127K | 108K | 40K | 4K | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -116.66M | -110.22M | -92.29M | -50.46M | -28.62M | -26.09M | -21.12M | -38.84M | -48.05M | -27.62M | -10.88M | -9.45M | -3.47M | n/a | n/a | n/a |
| Net Income | -116.66M | -116.88M | -92.29M | -52.17M | -31.09M | -29.36M | -21.12M | -38.84M | -48.05M | -27.62M | -10.88M | -9.45K | -3.47M | -17.72K | -30.87K | -21.13K |
| Selling & General & Admin | 34.75M | 30.21M | 23.47M | 14.35M | 10.64M | 8.76M | 7.95M | 10.44M | 12.66M | 9.04M | 6.24M | 4.08M | 2.22M | 13.72K | 13.87K | 14.02K |
| Research & Development | 86.66M | 81.88M | 68.84M | 36.16M | 18.19M | 17.56M | 13.34M | 28.53M | 35.5M | 18.62M | 4.65M | 2.58M | 1.16M | n/a | n/a | n/a |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.88K | n/a | 4K | n/a | n/a |
| Operating Expenses | 121.41M | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M | 21.29M | 38.97M | 48.16M | 27.66M | 10.89M | 6.66M | 3.38M | 17.72K | 13.87K | 14.02K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4K | 1.61M | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 229.55 | n/a | n/a | n/a | n/a |
| Cost & Expenses | 126.15M | 112.09M | 92.31M | 50.51M | 28.83M | 26.32M | 21.29M | 38.97M | 48.16M | 27.66M | 10.89M | 6.66M | 3.38M | 17.72K | 30.87K | 21.13K |
| Income Tax | n/a | 4.79M | -75K | -75K | -236K | 233K | -70K | -206K | -161K | -36K | -17K | 1.61M | 3.38M | 17.72K | 30.87K | 21.13K |
| Shares Outstanding (Basic) | 532.48K | 182.54K | 56.94K | 14.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 6.00 | 1.00 | 1.00 | 1.00 |
| Shares Outstanding (Diluted) | 532.48K | 182.54K | 56.94K | 14.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 6.00 | 1.00 | 1.00 | 1.00 |
| EPS (Basic) | -219.09 | -640.26 | -1.62K | -3.53K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -578.35K | -17.72K | -30.87K | -21.13K |
| EPS (Diluted) | -219.09 | -640.26 | -1.62K | -3.53K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -578.35K | -17.72K | -30.87K | -21.13K |
| EBITDA | -114.09M | -110.84M | -92.26M | -50.48M | -28.8M | -26.27M | -21.06M | -38.76M | -48M | -27.62M | -10.87M | -6.65M | -3.37M | -17.72K | -30.87K | -21.13K |
| Depreciation & Amortization | 4.29M | 1.25M | 50K | 27K | 26K | 54K | 64K | 206K | 161K | 36K | 17K | 14.33K | 9.3K | n/a | n/a | n/a |